VFT
PSTV

Vanguard Fiduciary Trust’s Plus Therapeutics PSTV Stock Holding History

Vanguard Fiduciary Trust’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$190K Buy
+46,551
New +$353K ﹤0.01% 3534

Other funds holding PSTV

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Fiduciary Trust's PSTV Position: Q1 2026 in Review

Vanguard Fiduciary Trust opened a new position in Plus Therapeutics (PSTV) in Q1 2026: 46,551 shares worth $190K. The stake represents ﹤0.01% of the portfolio and ranks #3534 among its holdings.

23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Vanguard Fiduciary Trust held 46,551 shares of Plus Therapeutics worth $190K as of Q1 2026.
  • Plus Therapeutics was a new Vanguard Fiduciary Trust position in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q1 2026, its #3534 holding.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q1 2026, filed 8 May 2026.